NCT01508364View on ClinicalTrials.gov

Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma

CompletedOBSERVATIONAL

Enrollment

20

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions

Carcinoma, Renal Cell

Interventions

DRUG

Sorafenib (Nexavar, BAY 43-9006)

Dosage according to label or at discretion of the attending physician

Trial Locations (1)

Unknown

Many Locations

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY